NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the <a ta ...

as they show great promise for NGGT002 to serve as a safe and effective treatment for PKU," said Yiting Liu, Ph.D., VP of Translational Research at NGGT. "With our initial 40-week span of positive ...

NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria WALNUT CREEK, Calif., Nov. 11, 2024 ...

(“Next Generation Gene Therapeutics” or “NGGT”), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced positive new data ...

"We are pleased with the results from our investigator-initiated trial, as they show great promise for NGGT002 to serve as a safe and effective treatment for PKU," said Yiting Liu, Ph.D., VP of ...

The country boasts 15 specialized metabolic disorder clinics, primarily located in urban centers such as Buenos Aires and ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

People with PKU can’t metabolize the amino acid phenylalanine, which is found in all protein foods. The current treatment for the disorder is a combination of medical foods and foods that are ...

The patents, based on these new findings, cover additional claims for Relief’s investigational drug RLF-OD032, a highly concentrated, novel liquid formulation of sapropterin dihydrochloride, for the ...